Please assess the completion status of the following clinical trial:

Trial Title: Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18 years~* Fulfill at least 4 of the 11 criteria for the ACR classification~* Any extra-renal flare with an SLEDAI\>6 and/or one BILAG A or 2 B~* Oral corticosteroids\>10 mg/day and HCQ \> 400 mg/day for at least 30 days prior to inclusion~Exclusion Criteria:~* Presence of active renal disease~* Previous intolerance or hypersensibility to any of the active components~* Active infection~* Unmeasurable levels of TMPT~* Pregnancy~* Presence of a severe flare that requires other immunosuppressive treatment for its control~* Any Psychiatric or social condition that did not ensure the patient´s follow-up and patient´s collaboration~* Previous treatment with EC-MPS or Azathioprine in the last 2 months~* Previous treatment with biological therapy in the last 3 months for anti-TNF therapy or in the last year for anti-CD20 therapy~* ALT or GPT \>120 UI/mL non-lupus related in the last 30 days~* Leucopenia \<1000x10E6 non-lupus related in the last 30 days~* Symptoms related to other medical conditions non-lupus related such as antiphospholipid syndrome.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- azathioprine (Type: ACTIVE_COMPARATOR): None
- Enteric-coated Mycophenolate Sodium (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).